Moderna-Merck Phase III cancer vaccine results prompt healthcare financing debate

Positive Phase III clinical trial results for a Moderna-Merck therapeutic cancer vaccine have shifted the focus toward the economic sustainability of high-cost precision medicine. The core uncertainty lies in how national health systems and insurers will structure reimbursement models for personalized immunotherapies.